Landmark Phase 3 Study of Xarelto Plus Aspirin Shows Significant Benefit in Patients with Symptomatic PAD after Lower-Extremity Revascularization - PharmaLive

Landmark Phase 3 Study of Xarelto Plus Aspirin Shows Significant Benefit in Patients with Symptomatic PAD after Lower-Extremity Revascularization  PharmaLive